Back
Transcenta Rises 2.4% After Dosing First Patient in Antibody Trial
Back
Stock News
Themes
Transcenta Rises 2.4% After Dosing First Patient in Antibody Trial
Transcenta Rises 2.4% After Dosing First Patient in Antibody Trial
Edgen Stock
·
Jan 14 2026, 17:22
Share to
Share to
Copy link
QYUNS-B
-1.46%
source:
[1] Transcenta Holding (02509.HK) completes first subject dosing in Phase I clinical trial for QX030N/CLD-423
Recommend
Citi Raises PBF Energy Target to $36 After 14.8% Stock Gain
Jan 17 2026, 06:20
Dow Appoints New CTO to Unify Tech and Sustainability Goals
Jan 17 2026, 06:10
Mediacom Founder Rocco Commisso Dies, Sparking Leadership Questions
Jan 17 2026, 06:05
Edgen Stock·Jan 14 2026, 17:22Edgen Stock·Jan 14 2026, 17:22
Edgen Stock·Jan 14 2026, 17:22